TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28364491

Group type: EXPERIMENTAL
Intervention: Sleep Intraindividual Variability (IIV) in Time-in-Bed (TIB)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Sleep Intraindividual Variability (IIV) in Sleep Onset Latency (SOL)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Mean Sleep Onset Latency (SOL)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Bedtime IIV
Number of subjects: 146

Group type: COMPARATOR
Intervention: Rise time IIV
Number of subjects: 146
Study: 25590501

Group type: EXPERIMENTAL
Intervention: Maternal death reviews and training on emergency obstetric care
Number of subjects: 191167

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 191167
Study: 23732550

Group type: EXPERIMENTAL
Intervention: MK-0773 50mg b.i.d.
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 21692640

Group type: EXPERIMENTAL
Intervention: Low-fluence, high-repetition Soprano® XL laser
Number of subjects: 42

Group type: COMPARATOR
Intervention: High-fluence, low-repetition LightSheer™ laser
Number of subjects: 42
Study: 19110600

Group type: EXPERIMENTAL
Intervention: Recombinant human adenoviruses expressing hypoxia-inducible factors (vascular endothelial growth factor and angiogenin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 16880093

Group type: EXPERIMENTAL
Intervention: Patients with HCM
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 30
Study: 12599221

Group type: EXPERIMENTAL
Intervention: Web-based social support group (Bosom Buddies)
Number of subjects: 72
Study: 10639202

Group type: EXPERIMENTAL
Intervention: Pulsed nebulization (2 mL of 0.5 mg mL(-1) or 2 mL of 0.25 mg mL(-1) budesonide)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Breath-synchronized nebulization (2 mL of 0.5 mg mL(-1) or 2 mL of 0.25 mg mL(-1) budesonide)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Constant output nebulization (2 mL of 0.5 mg mL(-1) or 2 mL of 0.25 mg mL(-1) budesonide)
Number of subjects: 22
Study: 9288387

Group type: EXPERIMENTAL
Intervention: Oxygen economizer tube
Number of subjects: 16

Group type: COMPARATOR
Intervention: Without oxygen economizer tube
Number of subjects: 16
Study: 8347899

Group type: EXPERIMENTAL
Intervention: Double-drug (methylprednisolone and azathioprine)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Triple-drug (methylprednisolone, azathioprine, and cyclosporine)
Number of subjects: 14
Study: 3524910

Group type: EXPERIMENTAL
Intervention: Adenoidectomy plus various combinations of ear operations
Number of subjects: 100

Group type: COMPARATOR
Intervention: Surgery confined to the ears
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 100

Group type: COMPARATOR
Intervention: No adenoidectomy
Number of subjects: 100
Study: 31658504

Group type: EXPERIMENTAL
Intervention: Automated positioning system for elution head in TLC/HPTLC-MS
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Elution of butyl paraben zones (5.4%, 10 ng/band)
Number of subjects: 70
Study: 28988341

Group type: EXPERIMENTAL
Intervention: Axitinib monotherapy (AXI)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Axitinib plus lomustine (AXILOM)
Number of subjects: 79
Study: 27529317

Group type: EXPERIMENTAL
Intervention: Glucose group (infused with acetated Ringer's solution with glucose at 2 mg/kg/min)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No glucose group (infused with acetated Ringer's solution without glucose)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Glucose group
Number of subjects: 80

Group type: COMPARATOR
Intervention: No glucose group
Number of subjects: 80
Study: 24841795

Group type: EXPERIMENTAL
Intervention: Single dose intravenous ozanezumab (0.01, 0.1, 1, 5, or 15 mg/kg)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Repeat doses of intravenous ozanezumab (0.5, 2.5, or 15 mg/kg)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Ozanezumab (0.01-15 mg/kg)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Repeat dose 15 mg/kg ozanezumab
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Ozanezumab treatment
Number of subjects: 76
Study: 22154769

Group type: EXPERIMENTAL
Intervention: Zoster vaccine (ZV)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 20482358

Group type: EXPERIMENTAL
Intervention: PubMed search for randomized controlled trials on orthodontic practice
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: High-quality randomized controlled trials identified
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Publication in four orthodontic journals
Number of subjects: 161
Study: 17682988

Group type: EXPERIMENTAL
Intervention: 15 infusions of 1 mg/kg (group A)
Number of subjects: 1485

Group type: EXPERIMENTAL
Intervention: 15 infusions of 0.75 mg/kg (group B)
Number of subjects: 1485

Group type: EXPERIMENTAL
Intervention: Daily administration of 1 mg/kg (group C)
Number of subjects: 1485

Group type: EXPERIMENTAL
Intervention: Daily administration of 0.75 mg/kg (group D)
Number of subjects: 1485
Study: 16244023

Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron IV
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 12.5 mg dolasetron IV
Number of subjects: 105

Group type: COMPARATOR
Intervention: 5 mL placebo
Number of subjects: 105
Study: 11981704

Group type: EXPERIMENTAL
Intervention: Ultrasonic scalpel (USS)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Argon-beam coagulator (ABC)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Conventional electrocautery (CEC)
Number of subjects: 93
Study: 9446843

Group type: COMPARATOR
Intervention: 500 mL of water (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 300 mL of table wine (28.4 g ethanol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 750 mL of table wine (71 g ethanol)
Number of subjects: 0
Study: 7648810

Group type: EXPERIMENTAL
Intervention: Non-proliferative retinopathy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Proliferative retinopathy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Males vs Females
Number of subjects: 200
Study: 2696457

Group type: EXPERIMENTAL
Intervention: Oxytocin titrated to achieve preset 'optimal' active contraction area
Number of subjects: 68

Group type: COMPARATOR
Intervention: Oxytocin titrated to achieve 'optimal' frequency of contractions
Number of subjects: 68
Study: 67975

Group type: EXPERIMENTAL
Intervention: Orally administered diamorphine every four hours at individually optimized doses in association with cocaine and a phenothiazine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Orally administered morphine every four hours at individually optimized doses in association with cocaine and a phenothiazine
Number of subjects: 0
Study: 30633317

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia using 25 and 26 gauge quincke and pencil-point spinal needles
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Physician experience and physical condition
Number of subjects: 613
Study: 29197204

Group type: EXPERIMENTAL
Intervention: HBM rehabilitation exercises
Number of subjects: 162

Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 162
Study: 25966305

Group type: EXPERIMENTAL
Intervention: Bicon(®) implants (6 or 8 mm)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ankylos(®) implants (8 mm)
Number of subjects: 20
Study: 24232701

Group type: EXPERIMENTAL
Intervention: Weight reduction programme
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study: 22960769

Group type: EXPERIMENTAL
Intervention: GnRH antagonist started on day 1 of stimulation (Group 1)
Number of subjects: 140

Group type: COMPARATOR
Intervention: GnRH antagonist started on day 5 of stimulation (Group 2)
Number of subjects: 140
Study: 20582874

Group type: EXPERIMENTAL
Intervention: Gelatin protein (0.6 g protein per kg bodyweight)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (water)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: GHRH injection (1 mu/kg body weight)
Number of subjects: 16
Study: 17019083

Group type: EXPERIMENTAL
Intervention: FX06 injection during and immediately after primary PCI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16061577

Group type: EXPERIMENTAL
Intervention: Outpatient family therapy for 6 months
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo intervention program
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Outpatient family therapy
Number of subjects: 22
Study: 12115176

Group type: EXPERIMENTAL
Intervention: CTLA‐4Ig (0.5 mg/kg)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: CTLA‐4Ig (2 mg/kg)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: CTLA‐4Ig (10 mg/kg)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: LEA29Y (0.5 mg/kg)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: LEA29Y (2 mg/kg)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: LEA29Y (10 mg/kg)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study: 10198864

Group type: COMPARATOR
Intervention: Topical ofloxacin 0.3% drops (3 preoperative drops given 10 minutes apart)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Collagen shield soaked in ofloxacin 0.3%
Number of subjects: 31
Study: 7774989

Group type: EXPERIMENTAL
Intervention: gemfibrozil 600 mg twice daily
Number of subjects: 27

Group type: COMPARATOR
Intervention: lovastatin 40‐80 mg once daily
Number of subjects: 27
Study: 1536333

Group type: EXPERIMENTAL
Intervention: Two 15-minute telephone calls approximately 1 to 3 weeks apart
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonintervention control
Number of subjects: 0
Study: 6380974

Group type: EXPERIMENTAL
Intervention: Bitolterol
Number of subjects: 28

Group type: COMPARATOR
Intervention: Isoproterenol
Number of subjects: 28
Study: 30819614

Group type: EXPERIMENTAL
Intervention: Harmonizing stomach to tranquilize mind acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 60
Study: 28925405

Group type: EXPERIMENTAL
Intervention: Intermittent energy restriction (INT)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Continuous energy restriction (CON)
Number of subjects: 51
Study: 26928727

Group type: EXPERIMENTAL
Intervention: Polypill (containing aspirin, statin and two antihypertensives)
Number of subjects: 413

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 413
Study: 28341619

Group type: EXPERIMENTAL
Intervention: ERPonline plus usual treatment
Number of subjects: 96

Group type: COMPARATOR
Intervention: Waitlist (WL) control plus usual treatment
Number of subjects: 96
Study: 22906798

Group type: EXPERIMENTAL
Intervention: Lithium monotherapy (initial dose: 600mg/d, adjusted to therapeutic levels)
Number of subjects: 46
Study: 21093140

Group type: COMPARATOR
Intervention: Standard Insertion Technique (SIT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard Insertion Technique with Jaw Thrust (SIT/JT)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Frontal Jaw Thrust Insertion Technique (FIT/JT)
Number of subjects: 70
Study: 19157547

Group type: EXPERIMENTAL
Intervention: Flow cytometry (FCM)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Real-time quantitative PCR of IG/TCR gene rearrangements
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: RT‐PCR detecting fusion gene transcripts
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: BCR‐ABL1 RNA level
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Flow cytometry (FCM) and IG/TCR rearrangement quantification
Number of subjects: 8
Study: 17150416

Group type: EXPERIMENTAL
Intervention: Electrochemotherapy with interferon‐alpha
Number of subjects: 8

Group type: COMPARATOR
Intervention: Monoimmunotherapy with interferon‐alpha applied three times weekly for a total of 4 weeks
Number of subjects: 8
Study: 15520346

Group type: EXPERIMENTAL
Intervention: Vaccine offered group
Number of subjects: 437

Group type: COMPARATOR
Intervention: Education only group
Number of subjects: 437
Study: 11281461

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (50 microgm, administered four hourly to a maximum of five doses)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Oral misoprostol (50 microgm, administered four hourly to a maximum of five doses)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 245

Group type: COMPARATOR
Intervention: Oral misoprostol
Number of subjects: 245
Study: 9771866

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1000 mg Ca/d as calcium citrate malate)
Number of subjects: 354

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study: 7787753

Group type: EXPERIMENTAL
Intervention: All transretinoic acid (ATRA) combined with intensive chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intensive chemotherapy alone
Number of subjects: 0
Study: 2159696

Group type: EXPERIMENTAL
Intervention: 7.5 g sodium propionate daily in capsule form
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dibasic calcium phosphate (placebo)
Number of subjects: 10
Study: 6784978

Group type: EXPERIMENTAL
Intervention: Dopamine (4 microgram . kg‐1 . min‐1)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Naloxone (20 mg infused over 3 h)
Number of subjects: 5
Study: 31154338

Group type: EXPERIMENTAL
Intervention: Free water protocol (access to water and ice)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (no access to water and ice)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Follow-up patients in rehabilitation (n = 15)
Number of subjects: 104
Study: 28892457

Group type: EXPERIMENTAL
Intervention: Romosozumab (210 mg monthly for 12 months)
Number of subjects: 4093

Group type: COMPARATOR
Intervention: Alendronate (70 mg weekly for 12 months)
Number of subjects: 4093
Study: 25794186

Group type: EXPERIMENTAL
Intervention: Single fluorescent phototherapy
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Double fluorescent phototherapy
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Single unit photodiodes
Number of subjects: 42

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 42
Study: 23348977

Group type: EXPERIMENTAL
Intervention: Screening strategy of the NELSON trial
Number of subjects: 200
Study: 20940517

Group type: COMPARATOR
Intervention: HSG/Mfn2 gene polymorphism (specifically SNPs rs873457, rs2336384, rs1474868, rs4846085, rs2236055)
Number of subjects: 1081

Group type: COMPARATOR
Intervention: HSG/Mfn2 gene polymorphism (specifically SNP rs4240897)
Number of subjects: 1081

Group type: COMPARATOR
Intervention: HSG/Mfn2 gene polymorphism (dominant model)
Number of subjects: 1081

Group type: COMPARATOR
Intervention: HSG/Mfn2 gene polymorphism (subgroup by sex)
Number of subjects: 1081

Group type: COMPARATOR
Intervention: HSG/Mfn2 gene polymorphism (allelic frequency of rs4240897)
Number of subjects: 1081

Group type: COMPARATOR
Intervention: C‐G‐A‐A‐A‐C‐C haplotype
Number of subjects: 1081

Group type: COMPARATOR
Intervention: Other haplotypes
Number of subjects: 1081

Group type: EXPERIMENTAL
Intervention: Body mass index and rs873457
Number of subjects: 1081
Study: 19217717

Group type: EXPERIMENTAL
Intervention: Full-time multidisciplinary programme (MDP)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Orthopaedic manual therapy and exercise programme (OMTP)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 2
Study: 17086362

Group type: EXPERIMENTAL
Intervention: Simvastatin plus niacin
Number of subjects: 34
Study: 15150954

Group type: EXPERIMENTAL
Intervention: Troponin-T quartiles
Number of subjects: 7800

Group type: EXPERIMENTAL
Intervention: C-reactive protein quartiles
Number of subjects: 7800

Group type: EXPERIMENTAL
Intervention: NT-proBNP elevation
Number of subjects: 7800

Group type: EXPERIMENTAL
Intervention: Creatinine clearance
Number of subjects: 7800

Group type: EXPERIMENTAL
Intervention: ST-depression at admission
Number of subjects: 7800

Group type: EXPERIMENTAL
Intervention: Multimarker strategy (creatinine clearance, troponin, CRP, NT-proBNP, ischemic ECG changes, clinical background characteristics)
Number of subjects: 7800
Study: 11222107

Group type: EXPERIMENTAL
Intervention: (99m)Tc‐labelled diethylenetriaminepenta‐acetic acid (DTPA)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: (113m)In‐labelled biotinylated DTPA (B‐DTPA)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Comparison of clearance rates of DTPA and B-DTPA
Number of subjects: 17
Study: 9363520

Group type: EXPERIMENTAL
Intervention: Self-reported diagnoses
Number of subjects: 5632

Group type: COMPARATOR
Intervention: Clinical confirmation by a specialist
Number of subjects: 5632
Study: 7911177

Group type: EXPERIMENTAL
Intervention: 100 micrograms gD2 in alum
Number of subjects: 98

Group type: COMPARATOR
Intervention: alum alone (placebo)
Number of subjects: 98
Study: 2402207

Group type: EXPERIMENTAL
Intervention: Glycerol (1 g.kg‐1 body weight) plus water (21.4 ml.kg‐1 body weight)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Water (21.4 ml.kg‐1)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Water (3.3 ml.kg‐1)
Number of subjects: 6
Study: 26100

Group type: EXPERIMENTAL
Intervention: Electropupillogram (E.P.G.) test dose of stimulant
Number of subjects: 3
Study: 31324209

Group type: EXPERIMENTAL
Intervention: Low-molecular weight heparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IRIS-AR intervention (Inform, Remind, Involve, Support)
Number of subjects: 0
Study: 28237426

Group type: EXPERIMENTAL
Intervention: Gene therapy (GT) with a second subretinal injection in the contralateral eye
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Functional MRI (fMRI)
Number of subjects: 7
Study: 25812482

Group type: EXPERIMENTAL
Intervention: Psychosocial Preventive Problem‐Solving Intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 23936037

Group type: EXPERIMENTAL
Intervention: Feminine women's faces and voices
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dynamic video clips of feminine and masculine faces and voices
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dynamic video clips of feminine and masculine voices
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Female stimuli
Number of subjects: 0

Group type: COMPARATOR
Intervention: Male stimuli
Number of subjects: 0
Study: 21803971

Group type: EXPERIMENTAL
Intervention: More frequent intradialytic hypotension
Number of subjects: 1426

Group type: EXPERIMENTAL
Intervention: Lower predialysis systolic BP
Number of subjects: 1426

Group type: EXPERIMENTAL
Intervention: Higher predialysis systolic BP
Number of subjects: 1426

Group type: COMPARATOR
Intervention: Intravenous hypotension
Number of subjects: 1426
Study: 18431534

Group type: EXPERIMENTAL
Intervention: Restricted elimination diet
Number of subjects: 27

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 27
Study: 16479339

Group type: EXPERIMENTAL
Intervention: Lichtenstein hernioplasty
Number of subjects: 139

Group type: COMPARATOR
Intervention: Kugel hernioplasty
Number of subjects: 139
Study: 15023571

Group type: EXPERIMENTAL
Intervention: Sarcosine (2 g/d)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 11685187

Group type: EXPERIMENTAL
Intervention: Nasogastric tube group (Group 1)
Number of subjects: 15

Group type: COMPARATOR
Intervention: No nasogastric tube group (Group 2)
Number of subjects: 15
Study: 9456664

Group type: EXPERIMENTAL
Intervention: Orapette SalivaCard HIV‐1/HIV‐2 antibody test
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Omni‐SAL/ImmunoComb II HIV 1 & 2 Saliva Test
Number of subjects: 615

Group type: COMPARATOR
Intervention: Serum samples tested by ELISA (Ortho)
Number of subjects: 615
Study: 7695268

Group type: EXPERIMENTAL
Intervention: Low dose of piperacillin-tazobactam (50 mg/kg piperacillin and 6.25 mg/kg tazobactam)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: High dose of piperacillin-tazobactam (100 mg/kg piperacillin and 12.5 mg/kg tazobactam)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both doses of piperacillin-tazobactam
Number of subjects: 47
Study: 3321586

Group type: EXPERIMENTAL
Intervention: Cyclosporine-prednisone (CsA-P)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Azathioprine-prednisone-antilymphocyte globulin (AZA-P-ALG)
Number of subjects: 224
Study: 29725975

Group type: EXPERIMENTAL
Intervention: Probiotic supplement (Familact®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27430216

Group type: EXPERIMENTAL
Intervention: Multidisciplinary self-care management program
Number of subjects: 40
Study: 23897021

Group type: EXPERIMENTAL
Intervention: 1.25 g·d of PEG‐creatine
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 2.50 g·d of PEG‐creatine
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 23820229

Group type: EXPERIMENTAL
Intervention: Dilute brimonidine (0.025%)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Naphazoline/pheniramine
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control (Systane Ultra)
Number of subjects: 180
Study: 20092840

Group type: EXPERIMENTAL
Intervention: Penile implantation without dilation (group 1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Penile implantation with dilation (group 2)
Number of subjects: 100
Study: 18762098

Group type: EXPERIMENTAL
Intervention: Endoscopic carpal tunnel release
Number of subjects: 13

Group type: COMPARATOR
Intervention: Open carpal tunnel release
Number of subjects: 13
Study: 15985272

Group type: EXPERIMENTAL
Intervention: Increased bilateral temporal lobe gyrification index in preterm children
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Left temporal gyrification index in preterm children
Number of subjects: 73

Group type: COMPARATOR
Intervention: Term controls
Number of subjects: 73
Study: 12499329

Group type: EXPERIMENTAL
Intervention: 12 mg lysine x kg(‐1) x d(‐1)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 30 mg lysine x kg(‐1) x d(‐1)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 18 mg lysine x kg(‐1) x d(‐1)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 36 mg lysine x kg(‐1) x d(‐1)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 24 mg lysine x kg(‐1) x d(‐1)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 42 mg lysine x kg(‐1) x d(‐1)
Number of subjects: 27